Mumbai, Maharashtra, India
Heightened awareness and knowledge about diabetes are boosting the acceptance of insulin therapy among people with type 2 diabetes. This, together with the emergence of innovative and effective diabetes management solutions, will act as a major driver for the insulin market over the coming years.
Frost & Sullivan (http://www.healthcare.frost.com) finds that the European Diabetes Market will earn revenues of $2.80 billion in 2005 and estimates this to reach $4.60 billion in 2012.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis of the European Diabetes Market (B935-52) then send an e-mail to Shwetha Thomas , Corporate Communications, at sthomas@frost.com with the following information: your full name, company name, title, telephone number, corporate e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.
"Technological advancements in the field of drug delivery have propelled scientists to research new and more convenient forms of insulin delivery," notes Frost & Sullivan Research Analyst Sylvia Miriyam Findlay. "The subsequent emergence of newer methods of insulin delivery including inhaled insulin, oral insulin, transdermal insulin will eventually expand the insulin market."
At present, the insulin market is at a growth stage, while the oral anti-diabetic market is in the mature phase. Despite cost barriers, nascent non-invasive insulin delivery technologies are set to stimulate overall market growth. Novel oral drugs such as the dual PPAR agonists, currently in the pipeline, are poised to gain market share due their efficacy.
Reimbursement limitations are currently restraining the uptake of these newer and more expensive forms of insulin. For instance, inhaled insulin and oral insulin are typically costlier than standard insulin vials and cartridges. With reimbursement for insulin devices and novel forms of insulin still uncertain, the penetration of such novel insulin delivery forms across the European Union will constitute a difficult task.
"Pharmaceutical companies need to work towards empowering diabetic patients to more effectively self-manage their condition," advises Ms. Findlay. "They need to aggressively provide value-added services to enhance product differentiation, while promoting end-user familiarity with products."
European Diabetes Market is part of the Pharmaceutical and Clinical Diagnostics Subscription, which also includes research in the following markets: Diabetes Drug Delivery Methods - Market and Technologies, European Central Nervous System Markets and, European Anti-Depressants Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.
European Diabetes Market
B935- 52
Shwetha Thomas, Corporate Communications - South Asia & Middle East, Frost & Sullivan, + 91 (022) 4001 3429 sthomas@frost.com
Radhika Menon Theodore, Corporate Communications - Europe, Frost & Sullivan, + 91 (044) 4204 4541 rmtheodore@frost.com
Source: Frost & Sullivan (Business Wire India)
Press release presented here is sourced from the Source mentioned above and is provided on as-is basis. Please contact the Company / Source directly for any further information in regard to this release. This website will be unable to assist you in regard to the accuracy or correctness of information in this release.
